A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors
© Larocque et al.; licensee BioMed Central Ltd. 2014
Received: 30 July 2014
Accepted: 8 October 2014
Published: 15 October 2014
Clostridium difficile is the leading cause of hospital-borne infections occurring when the natural intestinal flora is depleted following antibiotic treatment. Current treatments for Clostridium difficile infections present high relapse rates and new hyper-virulent and multi-resistant strains are emerging, making the study of this nosocomial pathogen necessary to find novel therapeutic targets.
We present i MLTC806cdf, an extensively curated reconstructed metabolic network for the C. difficile pathogenic strain 630. i MLTC806cdf contains 806 genes, 703 metabolites and 769 metabolic, 117 exchange and 145 transport reactions. i MLTC806cdf is the most complete and accurate metabolic reconstruction of a gram-positive anaerobic bacteria to date. We validate the model with simulated growth assays in different media and carbon sources and use it to predict essential genes. We obtain 89.2% accuracy in the prediction of gene essentiality when compared to experimental data for B. subtilis homologs (the closest organism for which such data exists). We predict the existence of 76 essential genes and 39 essential gene pairs, a number of which are unique to C. difficile and have non-existing or predicted non-essential human homologs. For 29 of these potential therapeutic targets, we find 125 inhibitors of homologous proteins including approved drugs with the potential for drug repositioning, that when validated experimentally could serve as starting points in the development of new antibiotics.
We created a highly curated metabolic network model of C. difficile strain 630 and used it to predict essential genes as potential new therapeutic targets in the fight against Clostridium difficile infections.
Clostridium difficile is an opportunistic, gram-positive anaerobic spore-forming pathogen found in the environment and in the intestinal flora in up to 3% of healthy adults. Toxigenic strains of C. difficile are resistant to a wide variety of antibiotics and produce the enterotoxin TcdA and the cytotoxin TcdB. These toxins are responsible for the clinical symptoms of C. difficile infection (CDI) ,. CDI is the leading cause of hospital-borne infections occurring when the natural intestinal flora is depleted following antibiotic treatment. CDI is the major cause of antibiotic-associated diarrhea and is responsible for pseudomembranous colitis, a form of severe intestinal inflammation. For the most part, CDI can still be treated with metronidazole or vancomycin for which resistance levels remain low or the recently approved fidaxomicin. Single or multiple relapses after initial treatment are common and bring about more severe symptoms. A recent clinical study reports a relapse rate of 24% and 13% with vancomycin or fidaxomicin treatment respectively . Between 50% and 80% of recurrences are due to spore-mediated re-infection . Unfortunately, patient-to-patient transmission and relapses are difficult to prevent due to the production of C. difficile spores that are resistant to antibiotics, heat, radiation and various chemicals.
CDI is directly responsible for an average 4.6 per 1000 patients admitted in hospitals with a 5.7% mortality rate after 30'days directly attributed to CDI . In the US, over 250,000 cases are registered per year in hospitals alone and many more cases in outpatient settings , costing around USD$4,000 to USD$8,000 per case of primary infection and USD$8,000 to USD$15,000 per relapsing infection  leading to a burden of over USD$500 million . More important than economic costs, CDI in older patients, those with concurrent debilitating conditions, and severely relapsing or fulminant cases may result in death.
In recent years there has been an increase in the rate of infections as well as the emergence of community-associated, virulent and antibiotic-resistant strains ,. Treatments of CDI that offer alternatives to the use of small-molecules  involving phages  or intestinal microbial flora transplants  are likely to meet resistance from patients. Others involving antibodies  or vaccines  are still under development.
The complexity inherent to preventing and treating CDI requires the continuous search for new ways to target C. difficile. In recent year, the growth of biological databases led to the development of the field of systems biology making it possible to build and analyze genomic-scale reconstructed metabolic networks . There is a large number of highly curated reconstructed metabolic networks for a number of organisms, from E. coli to human . The prediction of essential genes is often used to detect potential drug targets -. Two techniques, Flux Balance Analysis (FBA)  and Synthetic Accessibility (SA)  are among those available to predict essential genes at a genomic scale through in silico gene deletion studies. The comparison of results obtained with either FBA or SA and experimentally determined essential genes shows equivalent levels of accuracy with either technique around 94% for B. subtilis, 83% for S. cerevisiae and 60-70% for E. coli. The success rates are likely reflecting the quality of the metabolic network reconstructions.
The combination of systems pharmacology and metabolic network analyses can help predict off-target effects of drugs as well as open new opportunities with the repositioning of existing drugs . In the present study we create and validate a highly curated metabolic network reconstruction for the pathogenic C. difficile strain 630. We then utilize it to predict essential genes or gene pairs. We employ a combination of systems biology, bioinformatics and structural computational biology methods to detect potential human cross-reactivity targets for and detect small-molecules, including existing approved drugs that may bind a number of the predicted C. difficile targets.
Creation of the network
The genome of C. difficile strain 630 is composed of a circular chromosome of 4,290,252 bp coding for 3968 open reading frames (ORFs) as well as a plasmid of 7881 bp coding for 11 ORFs . The C. difficile strain 630 draft reconstructed metabolic network presented here covers 20.3% of the ORFs present in the chromosomal genome of the bacteria with 806 ORFs. These 806 genes code for proteins catalyzing 769 metabolic, 145 transport and 117 exchange reactions. A total of 592 unique metabolites (703 in total not considering extracellular or intracellular state) are involved in the 1031 reactions in the network. The coverage of the genome is similar to those of previously published reconstructed metabolic networks such as B. subtilis with 20%  and higher than the most recent network of C. acetobutylicum with 13.0% . Most reactions have at least one gene association (77.9%). Reactions without any gene association were added based on the existence of evidence from the literature such as in the case of Stickland reactions -, presence in databases such as xanthine amido hydrase or to fill functional gaps to obtain a functional network as in the case of putative transporters for end-products of fermentation.
The final version of the network is available in 3 different formats: 1. An excel file that shows on different spreadsheets the reactions, metabolites, genes, and compartments that comprise the network and the definitions of the network based on the standard described in the RAVEN toolbox . This file is meant to be easily readable by humans; 2. A tab-separated format of the network amenable to analysis in the R Statistical Computing environment (www.r-project.org) using Sybil ; and lastly, 3. A SBML Level 2 formatted network  that can be used with tools such as Matlab or other SBML compliant software. While a naming convention has been suggested recently for metabolic reconstructions , we feel that a naming convention that does not allude to the name of the organism is insufficient. Therefore, in the present work, the C. difficile strain 630 metabolic network reconstruction is called i MLTC806cdf as per the suggested convention with the added cdf suffix denoting the KEGG  three-letter organism ID representing C. difficile strain 630. The SBML version of the model has been deposited to the BioModels database  and assigned the identifier MODEL1409240004 .
Definition of the different media used in this study
Tryptophan, cysteine, isoleucine, leucine, methionine, proline, valine, R-pantothenate, Pyridoxine, biotin, glucose
Minimal plus thiamine, nicotinamide, Riboflavin, 4-aminobenzoate, folic acid, vitamin B12
BDM plus the 13 standard amino acids not listed in the minimal medium
All the components of the minimal medium, the remaining 13 standard amino acids, riboflavin, folic acid, inosine, vitamin B12, chorismate, glucose, glycerol-3-phosphate, ribose, hypoxanthine, deoxycytidine, uracil, uridine, dexoyadenosine, adenosine, thymidine
In order to validate the network, experiments involving the removal or addition of certain metabolites from the media were reproduced in silico. Each essential amino acid (cysteine, leucine, Isoleucine, proline, tryptophan and valine) was confirmed essential in the network as their removal prevented the production of biomass in any medium. None of the three essential vitamins are essential in the network (Additional file 1: Table S1). The essentiality of two of these, biotin and pyridoxine, is due to their implication in the regulation of processes which could not be simulated in the metabolic network. Panthothenate (which is important in lipid metabolism) was in the past determined to be essential for a number of C. difficile strains tested . More recently, a new ketopantoate reductase (KPR) gene panG was discovered in a number of pathogenic bacteria and found to have a homolog in C. difficile strain 630 . Therefore, whereas panthothenate is commonly thought to be essential, this essentiality is strain specific and absent in C. difficile strain 630. A ?panG mutant in Francisella tularensis did not have any differences compared to wild type infections in a mouse model for pneumonic tularemia . This is likely due to the fact that panthothenate (vitamin B5) is widely available in food and most bacteria are able to import panthothenate through a sodium co-transport mechanism .
Removal of non-essential metabolites did not have an important effect on growth. The non-essential amino acid methionine is known to enhance growth of the bacteria and is used in the minimal medium to increase growth rate. Interestingly, the removal of methionine from the minimal medium leads to a slight reduction in biomass production (less than 1%), a small but qualitatively correct effect. We simulated the removal of arginine and histidine (both non-essential amino acids) from the rich medium and in both cases this lead to the qualitatively correct result of a decrease in biomass production in agreement with the experimental evidence . Most (8 out of 11) non-essential amino acids that when removed from a complete media do not affect growth rate experimentally also have no effect in silico when removed from the complex medium. Furthermore, the addition of certain non-essential amino acids (8 out of 13) or any nucleosides to the minimal medium leads to an augmentation of biomass production in agreement with experimental data (Additional file 1: Table S1).
The utilisation of different carbon sources in the absence of glucose in the network was simulated and compared to experimental data. Such data is not always specific to C. difficile strain 630 and small differences among strains do exist  (Additional file 1: Table S2). The removal of glucose produced the largest decrease in biomass production (~33%) but had a smaller effect in the complex medium (~6%). For 15 experimentally tested carbon sources (out of 20 carbon sources tested in silico) we obtain 100% agreement between the predicted utilization of alternative carbon sources by C. difficile, including the impossibility to use lactose as a carbon source. Furthermore, we predict that C. difficile strain 630 should not be able to use rhamnose or myo-inositol (for which there is some evidence of usage in other strains but no experimental information for strain 630) while malate, glycerol and chorismate would lead to increased growth rates.
Comparison with existing metabolic network reconstructions
Comparison between the automatic C. difficile , i MLTC806cdf and C. acetobutylicum networks
C. acetobutylicum iCAC490
With an EC number
With KEGG ID
Identified as unclear reaction
Associated with multiple reactions
Involving generic metabolites
Unique reactions in common
With KEGG ID
Unique metabolites in common
With a homologa
Loci linked to multiple entries
Unique loci in common
We also compared i MLTC806cdf to a curated metabolic network reconstruction of the closely related bacterium Clostridium acetobutylicum. Three curated metabolic networks exist for this organism ,, all focusing on metabolic engineering of the bacteria to maximize the production of butanol. The latest network , called i CAC490, was chosen for the comparative analysis as it was the largest, the most recent and the only one available in a commonly accepted usable format (SBML). The analysis of reactions shared between the two reconstructions was possible due to the extensive use of KEGG identifiers in both networks. In the case of transport reactions, two transporters were considered similar if they transported the same molecule with one transporter from one network potentially matching multiple transporters in the other network. We did not differentiate between phosphoenolpyruvate (PEP):carbohydrate phosphotransferase system (PTS) , ion channels  or ATP driven transporters  as long as the transported molecules were the same in the two networks. i MLTC806cdf contains 174 more reactions than the reconstructed network of C. acetobutylicum and 416 in common with it (representing 45.5% of our reactions). i MLTC806cdf has 62 less unique metabolites and 389 metabolites in common (representing 66% of our unique metabolites). The presence of 186 (28% of the metabolome) dead-end metabolites (a complete list can be found in Additional file 1: Table S3) suggests that the C. acetobutylicum network still has incomplete pathways and gaps that could affect biomass production. A detailed comparison is presented in Table 2 or in the form of a Venn diagram in Additional file 1: Figure S2.
Single gene deletions
We performed an in silico gene deletion study using both Synthetic Accessibility (SA) and Flux Balance Analysis (FBA) on i MLTC806cdf in order to identify potential essential genes that may lead to the discovery of novel therapeutic targets. This analysis removed reactions that were catalyzed by each gene alone (or in pairs, next section) or by a complex that involved that gene product and then measured the capacity of the network to produce biomass (either a flux in biomass production for FBA or Snet for SA, see Methods). The complex medium (as describe in Table 1) was the one used for the gene deletion studies since it reproduces the high concentration and diversity of nutriments found in the intestinal tract. Furthermore, the medium used is the same as the simulation of the Bacillus subtilis metabolic network , which in turn is an approximation of the one used to perform the experimental validation of lethality of single gene deletions in that organism .
List of 76 predicted C. difficile essential gene and essentiality of their B. subtilis homologs
Essentiality ofB. subtilishomolog
PredictedC. difficileessential genesa
accA3, accB3, accC3, accD3, acpS2?, adk2?, asd 3, cdsA3, cmk2, coaE3?, dapF 3, dapH 3, ddl 3, dxr 3, dxs 3, fabD 3?, fabF 3?, glmU3, gmk3, guaB2, ispD 3, ispE 3, ispF 3, ispG 3, ispH 3, metK2, mnaA3, murA 3?, murB 3, murC 3, murD 3, murE 3?, murF 3, murG 3, nadD3, nadE 3, pgsA 3?, plsX3, prs3, CD0119 3, CD0244 3*, CD10493, CD24393, CD35432, CD35503*, pgk1 (15.48%)
coaBC3, coaD3, crt13?, fabH 3, fabZ3, guaA3, ispA3, metF1*, pdp3*, ribC3?, CD05572?, CD19663*, CD2256 2*, CD25412*, CD2549 2*?, CD35553, CD35961, pykF1 (15.51%), CD09941*? (15.08%), serA1? (15.08%), ackA 1 (14.74%), asnA1? (5.76%)
No B. subtilis homolog (8)
cat1 1*, ntpA1* (10.31%), ntpB1 (10.31%), ntpC1 (10.31%), ntpD1* (10.31%), ntpE1* (10.31%), ntpF1* (10.31%), ntpK1* (10.31%)
Essential genes were compared to experimental results for the gram-positive bacteria Bacillus subtilis, which is the closest relative of Clostridium difficile with experimental essentiality data for all of its genes. Since the simulation involved the deletion of genes via deletion of metabolic reactions, functional homologs (genes responsible for reactions that share the same EC number and catalyze similar reactions) were used for the comparison. Among the 76 genes with a predicted effect on biomass production in C. difficile, 46 have homologs that are essential in B. subtilis, 8 did not have any functional homolog and 22 had a homolog that was not essential in B. subtilis (Table 3). We were able to compare 618 C. difficile genes (76.8% of the genes in i MLTC806cdf) for which we could detect a B. subtilis functional homolog with an overall prediction accuracy of 89.2% (Additional file 1: Table S4). A similar rate of 89.0% was obtained based on the comparison of 525 genes using sequence homology (E value <1e?5, sequence identity above 30% and alignment overlap over 80% of the C. difficile sequence, Additional file 1: Table S4). While an accuracy of around 89% is extremely high, it is important to keep in mind that despite being closely related, differences are expected between the B. subtilis and C. difficile.
We utilized i CAC490 to perform the prediction of essential genes in C. acetobutylicum and compared the results to those above for C. difficile. Essential genes in the C. acetobutylicum network were identified in a similar manner than in i MLTC806cdf, using Sybil  within the R environment for statistical computing. Of the 658 C. difficile proteins with C. acetobutylicum sequence homologs, 368 are present in i CAC490. Based on these 368 proteins, we obtain an agreement of 72.3% between i MLTC806cdf i CAC490 (Additional file 1: Table S5). It is interesting to note that we obtain a higher agreement between our computational results for C. difficile and experimental results for B. subtilis than with computational results for i CAC490 representing a more closely related species.
The difficulty of performing genetic manipulations in C. difficile is notorious and severely restricts our ability to compare our results with experimental information. Despite the lack of extensive information on experimentally verified essential genes, the little evidence that exists, supports our predicted essential roles for a number of genes: metK , guaA  and ntpA-B-C-D-E-F-K . Other known essential genes such as secA1-A2 , metG and gyrA-B , trpS  and gldA  are not present in the network and are involved in non-metabolic processes. Lastly, the gene prdF has been mutated and was shown to be non-essential , in agreement with its predicted non-essential role in i MLTC806cdf.
We compared the list of 76 genes predicted to be essential in C. difficile using i MLTC806cdf to the genes in the Database of Essential Genes (DEG) . Interestingly, and serving as further validation of i MLTC806cdf, a total of 61 of these genes are present in DEG, i.e., these genes have homologs known to be essential in other species. The remaining 15 predicted essential genes that are not present in DEG (Table 3) include ntpA,D,E,F,K (all subunits V-type ATP synthase) as well as metF (involved in amino acid synthesis) and xpt (guanine synthesis) among others (Additional file 1: Table S6).
The inhibition of the product of essential genes that are upregulated during CDI may require a smaller drug dose to generate an effective response, thus decreasing side effects. We utilized transcriptomics data associated to the differential expression of genes during infection  to annotate predicted essential genes in view of their potential use as therapeutic targets. Eight predicted essential genes are downregulated in vivo while 6 are upregulated during infection. Some of the genes that are upregulated during infection and predicted to be essential such as fabD, serA or CD2549, are of additional interest as they could not only affect growth, but also colonisation and pathogenesis processes  (Table 3).
Detection of potential human cross-reactivity targets
Sequence and functional similarities
One of the main goals in detecting essential genes is to assess their potential as therapeutic targets. One factor weighting in favour of a potential therapeutic target is the lack of a human homolog, as this decreases the chances of side effects of a potential drug off-targeting the gene product of the human homolog. We again utilize here two definitions of homology, the standard sequence homology that relates two genes through evolution and functional homology, which relates two genes via common function of their gene products, specifically the same E.C. number. Functional homology is stricter than sequence homology as it is not based on any level of similarity between the two proteins, only based on the fact that the two enzymes catalyze the same reaction. Fifty-four genes have no sequence homologs in H. sapiens. Thirty of these have functional homologs, while 24 genes identified as potential targets do not have any human functional or sequence homolog (Additional file 1: Table S6).
Local structural similarities
There is a possibility that potential cross-reactivity targets may perform different functions (EC numbers) and have little sequence similarity yet still have sufficient 3D atomic binding-site similarities to be inhibited by a drug developed against a C. difficile target. We proceeded to analyse binding-site similarities to detect potential cross-reactivity targets for the 24 C. difficile proteins where sequence or functional similarity search did not detect any human homolog. Binding-site similarities are measured in terms of detected geometrically and chemically equivalent atoms in common between two binding-sites ,. We found an average of 36 atoms in common between binding-sites (average p-value 0.038 and z-score 3.05) for 21 out of 24 models with members of Pfam families  that include human proteins. In three cases, ispF, CD2549 and dapH, no significant level of binding-site similarity was found to a Pfam family that contains human homologs (Additional file 1: Table S7).
The inhibition of potential human cross-reactivity targets detected by sequence, functional or 3D binding-site similarities may not necessarily lead to any serious side effects. As a result of the differences between human and C. difficile metabolism, a protein may be essential in the former but non-essential in the later. We sought to use FBA to determine if inhibition of human homologs of predicted essential C. difficile proteins could have any effect on the human cell. To do so, we performed a gene deletion FBA analysis on the latest draft of the human reconstructed metabolic network RECON2 . In the case of functional homologs all reactions associated to the human homolog of the C. difficile target were removed for the FBA analysis from the human network. Likewise, in the case of the 21 C. difficile potential targets without human functional homologs but with detected binding-site similarities, we identified all human proteins from the Pfam families where similarities were detected and deleted all RECON2 reactions associated (from 1 to 121 reactions at once depending on the C. difficile protein). We opted for this conservative approach to simulate a situation in which a potential drug would inhibit all potential cross-reactivity targets. Only 4 predicted essential C. difficile genes have predicted essential human cross-reactivity targets (underlined in Table 3). For all others, the presence of a human potential cross-reactivity target may not be sufficient to discard it as a potential target.
Double gene deletions
We performed double gene deletions to identify potential polypharmacological targets and to target reactions that are catalyzed by isoenzymes. Based on FBA analysis, 203 gene pairs involving 69 unique genes that had small or no effect in single gene deletion were deleterious when removed in pairs. An additional 3 essential gene pairs involving 6 new unique genes were found using SA. Eight gene pairs were considered essential in both SA and FBA (Additional file 1: Table S8).
Isoenzymes usually result in a higher biomass loss than relatively distant pairs (Figure 2). For the 12 isoenzymes, the deletion of the two genes in a pair is required to remove a reaction that is catalysed by both. For the remaining essential gene pairs, the reactions associated with both genes are used in parallel in the wild type, a case of metabolic plasticity , or the reactions from only one of the genes is used while the reaction from the other member of the pair can act as a backup, a case of metabolic redundancy . Depending on the category in which an essential gene pair falls, different strategies may be required in order to target the pair . From the 39 essential genes pairs, 23 represent cases of plasticity of the network and 4 cases of redundancy in the network (Additional file 1: Table S9).
Distribution of predicted essential genes across pathways
Potential compounds binding predicted essential targets
List of 29 potential targets associated with 125 potential binders based on sequence identity
DrugBank potential inhibitorsc
LZJ, LZK, LZL, OA1, OA2, OA3, OA4, OA5, L21, L22, L23 (P24182 [53%]); BTI (Q99UY8 [48%]); BTN (P11498 [45%]); D1L, H1L (O00763 [32%])
IPE (P30085 [32%])
QUE (Q6NVY1 [30%])
CER, P9A, PMN (P0AAI5 [50%]); TL5, TL6, P4T (P0A953 [38%]); TLM (P63454 [37%])
CER, 669, OCS (P0A6R0 [45%]); B82 (820 T1 [43%]); DCC, UDT, VZZ, D1T, DFD, MDX (P0A574 [37%])
QUE, 2BC, 2BE, 2RB, 3BE, 4BB, 4BE, AGI, EMO, SAK (Q5G940 [41%]); BDE (O25928 [41%])
P21 (P43889 [42%])
MOA, RBV, CPR, VX-148 (P20839 [35%])
IPR (Q83M58 [41%])
DMA, IPE (P62624 [30%])
FPP (Q8EBR3 [62%]); GPP (P62617 [55%]); IPP (A0R559 [34%])
LK1, LK2, LK3, LK4, LKM (P14900 [32%]);
ADH, 911, Tiludronate, BafilomycinA1, Bafilomycin B1 (P38606, [51%]); QUE, APP, AUR, PIT, TLX (P06576 [30%])
Gallium nitrate, AES (P21281 [53%]); QUE, APP, AUR, PIT, TLX (P06576 [30%])
D8G, DYY, DZG, PGA (P14618 [44%])
deoD (deoB, deoC)
IMH, 2DI, AZG, 9PP, IMG, GU7, BC3, 9DI (P00491 [48%])
EMO (P16544 [37%]); TAQ, CB3, DVP, FE1 (P0CG22 [34%]); MAX (Q6PKH6 [33%]); TDB (Q16698 [31%])
TCL, IDN, AYM, BGC, 654, ZAM, 826, NDT, (P0AEK4 [39%]); NAP, TDB (Q16698 [30%])
BRZ, NMD, TND (O14556 [44%]); AES (P04406 [49%])
APR, SND, AES (P04406 [49%]); BRZ, NMD, TND (O14556 [47%])
B08, B28, B29, B76, FPP, FPS, IPE (P60472 [44%]); GPP (P60379 [43%])
PLP, THL (P34897 [45%]); Mimosine (P34896 [44%])
PLP, THL (P34897 [41%]); Mimosine (Pr4896 [40%])
CD0727 (folD | fhs | fchA)d
CNC, THL, I2A (Q99707 [31%])
scoB (folD | fhs | fchA)d
SIN, EMT (P55809 [52%])
scoA (folD | fhs | fchA)d
SIN, EMT (P55809 [42%])
DX4, PPO, PM6, PRP, XMP, 9DG (P00492 [34%])
DX4, PPO, PM6, PRP, XMP, 9DG (P00492 [34%])
RLT, 1O8, DTT (P00352 [30%]);
In this work we present i MLTC806cdf, a highly curated metabolic network of the nosocomial pathogen Clostridium difficile strain 630. This metabolic network is functional in the sense of being amenable to simulations using Flux Balance Analysis to measure biomass production in diverse types of media. i MLTC806cdf is available in SBML, TSV and Excel formats. The network is based on the aggregation of metabolic data present in databases, augmented with information from various sources of experimental data from the literature and manually curated in order to ensure a high quality of the resulting network.
Metabolic networks bring together information from various databases. Due to inaccuracies, contradictions and missing information in each database -, the non-curated network resulting from the simple aggregation of all these sources of information is often incomplete and includes a large number of errors, missing data and repetitions, which make the generated networks unusable . Different databases will often have multiple identifiers for highly similar entries, which cause duplications. Surprisingly, this is true not only for reactions and metabolites where curation is more difficult but also for genes. Manual curation is essential to correct inaccuracies present in metabolic databases and particularly to fill gaps (missing reactions) necessary to remove dead-end metabolites to create a functional network. Manual curation is a time consuming, expensive and non-scalable process. Unfortunately, it is also indispensable at this time as can be attested by the 14 predicted essential genes (alone or as part of a double mutant) that do not even appear in the automatically generated C. difficile network. It is clear that the automated generation of functional metabolic networks is a worthwhile goal. However, at present automatically generated networks are not functional. At this time, such networks can only be used at best as a starting point prior to intensive manual curation. Their use as starting points however subtracts very little to the manual work required to produce a functional network.
In some sense, metabolic networks serve as a tool to aggregate all existing knowledge about the metabolism of an organism. Clearly, the more well studied an organism is, the more information exists to build and validate such a network. C. difficile is an organism that is not well studied due to a number of factors. First, being a pathogen severely restricts the number of active researchers studying it given the experimental requirements in terms of biosafety. Second, C. difficile presents particular challenges that make genetic manipulations notoriously difficult. Until recently, genetic studies in C. difficile were restrained by the lack of efficient tools to inactivate specific genes. The recent development of a universal gene knockout system in clostridia has opened new possibilities and it is now somewhat easier to disrupt genes in a very specific and directed manner ,. This system called ClosTron is based on retargeting of the Lactococcus lactis Ll.LTRB group II intron so that upon transfer into C. difficile by conjugation, the intron integrates at a specific user-defined chromosomal site. With the advent of ClosTron our knowledge of the biology of C. difficile and the identification of essential genes is bound to increase but at the moment, there is a lack of C. difficile specific literature and that limits the completeness and validation of the network. Some information such as biomass constituents and protein-protein interactions had to be extrapolated from other closely related species. The metabolic pathways involved in linking dead-end metabolites to the rest of the network also sometimes had to be extrapolated due to lack of experimental data. No in-depth studies exist of the directionality of reactions as it was done in E. coli, or association between biomass production and predicted growth rate as it was done in B. subtilis, due to the absence of metabolomics data and precise growth rate experiments for C. difficile. While information can be extrapolated from closely related organisms, fundamental differences still exist and may be a source of potential errors. Notwithstanding the existing limitations in creating and validating a C. difficile specific network, i MLTC806cdf is as complete or more than existing curated networks and accounts for all existing relevant experimental information. We hope that in addition to being a tool to aggregate existing knowledge, i MLTC806cdf will prove to be valuable as a nucleation point in developing our understanding of this important human pathogen driving the generation of new experimental hypotheses.
The analysis of a metabolic network in isolation in the absence of other relevant processes present in the organism poses its own problems. For example, the effect of metabolites (such as pyridoxine and biotin)  involved in non-metabolic processes could not be simulated. Likewise, methionine added to minimal media greatly increases growth in vitro but the addition of methionine to the minimal media in i MLTC806cdf increases biomass by less than 1%. Methionine is mostly used in the bacteria as S-adenosyl methionine involved in the biosynthesis of cofactors and vitamins which are not directly involved in biomass synthesis and have an effect that cannot be simulated in the metabolic network . While the removal of methionine produced a qualitatively correct outcome, the loss of biomass in the network when removing methionine from the minimal medium is only due to the additional reactions required to produce enough methionine as required for biomass production.
The case of pantothenate, the only essential vitamin with a clear metabolic effect is unique, as its essentiality is strain-dependant. A biosynthesis pathway for panthothenate was recently identified in C. difficile strain 630  and is present in some other strains based on MetaCyc. As a result, this vitamin is a non-essential component of the growth medium based on our in silico analysis. This vitamin is however essential in a number of strains previously tested , which did not include either strain 630 or the others containing this pathway in MetaCyc.
The comparison with C. acetobutylicum network  indicates that both bacteria share the same metabolic core. Existing differences in reactions and associated genes may explain the differences obtained while comparing the effects of deleted genes and reactions. The different media utilized for both bacteria may also cause some differences.
The comparison with experimental results for B. subtillis was used as validation due to the absence of experimental results for the gene essentiality in C. difficile. While essential differences exist between the two organisms, a large degree of conservation is also present. Therefore one should expect that a large number of genes conserve their essentiality across these two species. The high level of accuracy (according to functional or sequence homology) between the experimental results and our predictions serves as a validation of i MLTC806cdf as a mature draft metabolic network and increases our confidence in the list of predicted essential genes. One important difference between the metabolism of C. difficile and B. subtilis is that the later can use oxygen to produce energy while the former cannot. Therefore, predicted essential C. difficile genes involved in fermentation such as pykF or ackA are not essential in B. subtilis. Other genes such as fabH, CD1966 and ribC are only present in one copy in C. difficile while more than one gene catalyses the same reactions in B. subtilis, explaining why such genes are non-essential in the latter.
Some genes whose inactivation is deleterious in vitro are not identified in silico due to their implication in non-metabolic processes. Both i MLTC806cdf and the network of Bacillus subtilis fail to identify the essentiality of CD1536 (yumC in B. subtilis) due to its implication in regulatory processes. In addition, the toxicity of a molecule cannot be simulated in silico either. Therefore, the essentiality of genes involved in detoxification or whose deletion leads to the accumulation of toxic molecules cannot be simulated. For example, the removal of CD3543 would lead to an accumulation of nicotinate that could be toxic. This effect cannot be simulated in the network, therefore CD3543 is not considered essential in the network but is essential in vivo in B. subtilis.
The combined use of FBA and SA allowed us to detect more essential genes than using either technique alone. Their joint use increases our confidence on the predictions for those genes where the two techniques agree. At the same time, the two techniques complement each other. For example, the gene acpS catalyses the only reaction that leads to the production of a holo-acyl-carrier protein from the apo version of the protein. This reaction is essential since the holo form of the protein is required to perform the elongation of lipids. The presence of a cycle that allows for the reutilisation of the released holo-acyl-carrier protein at the end of lipid elongation prevents FBA to identify the deletion of acpS as deleterious. The analysis by SA uses the apo version of the acyl-carrier protein and predicts acpS as essential since without it, the holo form cannot be produced. New targets were also found when using SA for double mutants. Targets identified by SA are mostly isoenzymes that lead to deletion of new reactions in the shortest possible pathway leading to the production of essential biomass metabolites.
The gene deletion analysis identified interesting potential therapeutic targets. Targets such as the aspartate-semialdehyde dehydrogenase (E.C. 126.96.36.199) asd (UniProt ID Q17ZW9) or the diaminopimelate epimerase (E.C. 188.8.131.52) dapF (UniProt ID Q182T1, also known to be essential in B. subtilis) that do not have human functional homologs, decrease the chance of side effects due to cross-reactivity. Another predicted essential gene, the aspartate-ammonia ligase (E.C. 184.108.40.206) asnA (UniProt ID Q183C9) is up-regulated in vivo and could be important for the pathogenesis of the bacteria . Most targets like CD2549, dxr and ispF have more than one of these characteristics and would be interesting for more than one reason.
As a result of the conservation of local binding site environments ,,, drugs often targets proteins in a way that might not be sequence-dependent. To account for that effect, we used functional homologs to identify potential human cross-reactivity targets for predicted essential C. difficile proteins. This made for a more stringent analysis since the number of potential human functional homologs is almost twice as large as those based on sequence similarity alone. The absence of a human homolog is often used as a criteria for identification of potential drug target . If no homolog is present, there is a smaller probability that a drug targeting this specific protein have an effect in humans.
For those cases where sequence or functional homology did not detect potential human cross-reactivity targets, we utilized the detection of local binding site similarities. This analysis identified protein families with human representatives that harbour large binding-site similarities to the C. difficile targets in the absence of sequence or functional similarities. The detected similarities are primarily localized to binding-sites of cofactors and ubiquitously used ligands such as NADP or ATP. It is important to keep in mind that it is not possible to determine a minimum similarity threshold other than 100% above which one can be certain that the detected human proteins will act as cross-reactivity targets as small differences can bring about drastic effects .
The presence of a human potential cross-reactivity target (a homolog or a protein with sufficient binding-site similarities) is not sufficient to evaluate whether or not targeting a particular target might have important side effects since the human protein might not be essential. The use of predicted essentiality of human functional homologs or those with detected binding-site similarities in RECON2  in conjunction with their essentiality in C. difficile represents a more consistent analysis of targets across hosts and pathogens. To our knowledge this use metabolic networks across species to determine the potential of a target to have cross-reactivity targets leading to side effects is novel.
A ‘perfect’ predicted essential target would be one without (or with non-essential) potential cross-reactivity targets in human and E. coli (as a proxy for gram-negative and gut flora in general), with essential homologs in B. subtilis and up-regulated in vivo. Although no C. difficile target could be found fulfilling all properties at once, the 123 potentially essential targets identified (as single or double mutants) fulfil several of these properties and could, once validated experimentally serve as a target for the development of new antibiotics.
The list of active molecules that potentially bind predicted essential targets includes many molecules that could help in the validation of the targets in C. difficile and the development of novel drugs . Experimental validation is required to determine if the identified small-molecules do bind the C. difficile homologs. Some of these small-molecules, such as the approved anti-viral Ribavirin, could speed the approval of C. difficile specific inhibitors through drug repositioning. In the case of Ribavirin, the molecule is a rapidly absorbed guanosine analog currently used in the treatment of Influenza  and hepatitis C . Cerulenin has anti-fungal and anti-bacterial activity targeting FabF in B. subtilis, thus very likely targeting the same protein in C. difficile as we predicted. In all cases, the multiple small molecules predicted to bind the predicted essential C. difficile proteins could be used to bias library selection for the rational development of new inhibitors.
In the current work we present the first extensively curated metabolic network reconstruction for C. difficile (strain 630) i MLTC806cdf and validate it with experimental data on essential metabolites and carbon sources. We compare i MLTC806cdf to existing networks showing the importance of manual curation and use the network to predict essential genes. The predictions agree with experimental data for B. subtilis (the closest organism for which such data is available). We detect potential cross-reactivity targets for each of these genes using a variety of methods combining systems and structural computational biology and determine that for only 4 out of 76 predicted essential genes, if exiting, the potential human cross-reactivity targets are themselves essential in the human metabolic network reconstruction RECON2. For a number of essential genes we find potential binding small molecules, including approved drugs such as Ribavirin, which may inhibit the respective gene products. We hope that i MLTC806cdf will find further use in the community and the results here lead to the development of novel antibiotics against C. difficile infections.
Creation and curation of the draft metabolic network
We created a collection of metabolic and transport reactions associated with C. difficile strain 630 from the KEGG , MetaCyc  and TransportDB  databases. Reactions involving polymers (glycogen, peptides and others) were ignored to avoid the spontaneous creation of matter due to the presence of molecules of undefined length. Also, some of these polymers, like glycogen, are only used for energy storage  and would not have any impact in simulations that optimize biomass production. Reactions involved in spore formation, the conjugation process, RNA, peptide or DNA modification, cell repair, and other non-metabolic enzymatic reactions were not added to the network since these reactions are not directly contributing to the production of biomass constituents. Finally, the reconstructed network concentrates solely on metabolism without including signalling, gene regulation and post-translational modification of proteins even if these can clearly affect metabolism.
Most transport reactions were based on TransportDB  although putative transporters not present in the databases had to be added for molecules known to be exported or imported by the bacteria. An exchange reaction (reaction that simulates interaction with the media via the appearance or disappearance of the given metabolites in the network) was created for each metabolite with an extracellular version. These exchange reactions are set to allow the export of a metabolite unless it is part of the tested growth medium in which case import is also possible.
The curation not only involved the addition and suppression of reactions from the initial draft, many characteristics of each reaction such as the directionality, the presence of complexes or the assignment of gene-reaction associations and their inclusion as part of a pathway had to be analyzed manually. The directionality of reactions was based on information obtained from the MetaCyc database when available. Reactions found exclusively in KEGG were kept bidirectional unless leafing to the production of a highly energetic compounds (ATP, NAD+, NADP+, etc.) that were not known to be produced in such a manner. Examples of reactions producing highly energetic compounds are ATP synthases, amino acid fermentation and glycolysis.
Protein-protein interactions are highly important in the network since they can modify the essentiality of a gene based on knowledge of the involvement of its protein product as part of a protein complex. The possibility that a protein complex is responsible for catalysis was investigated for every reaction that had more than one gene associated to the reaction and for any gene whose protein is identified as a subunit of a complex. We used information from TransportDB, UniProt, Brenda and literature data (either for the C. difficile protein of interests or a homolog of same function that could indicate a similar interaction between genes products). In every case the STRING version 9.1  score was calculated to evaluate the confidence score attributed to each complex (Additional file 1: Table S13).
We used KEGG pathway identifiers since they are generic and allow maintaining a small number of pathways in the network. Pathways containing less than five reactions were manually merged to the closest relevant pathway. Reactions that were not associated to any pathway in KEGG (32% of the reactions in KEGG) were linked to existing pathways. The pathway assigned to the reaction was the one in which the less linked metabolite of the reaction was most often present in the network (Additional file 1: Table S10).
Lipid biosynthesis and cell membrane composition
A problem with lipid biosynthesis in metabolic networks is the fact that a variety of different fatty acids exist in cells with different lengths and saturation states and can be used in numerous cellular processes, both metabolic and non-metabolic. Also, the lipid composition of the cellular membrane is a mix of various phospholipids and glycerolipids of varying lengths and composition and this composition varies depending on the growth conditions . A complete definition of lipid metabolism is likely impossible to define at this moment given the lack of experimental information specific to C. difficile membranes. Furthermore, the resulting network would be dominated by lipid reactions with the same few genes repeated for every possible length and saturation state for every lipid type. Therefore, having an exhaustive definition of lipid metabolism would not bring any additional relevant information on metabolism. In most reconstructed metabolic networks, lipids are used almost exclusively in membrane formation. Following , in order to reduce the complexity of lipid metabolism while keeping it as close to the real bacteria as possible, the fatty acid composition of all lipids is held at a constant 16:0 (carbon chain length: number of double bonds), which is the most abundant fatty acid observed in C. acetobutylicum. The last step in simplifying lipid biosynthesis was to combine the elongation of fatty acids from acetyl (2:0) to palmitate (16:0) into a single reaction and beta-oxidation of the palmitate back into acetyl as another single reaction.
In order to simulate bacterial growth, the biomass (ensemble of macromolecules necessary for cellular growth and division) composed of DNA, RNA, cell wall, proteins, solute pool and lipids was defined based on the following elements. Nucleic acid composition of DNA used in the network was calculated based on the nucleotide content of the genome and plasmid of Clostridium difficile strain 630, RNA composition is based on the content of the transcriptome using the UCSD genome browser  and protein composition using the proteome. Lipid, cell wall and solute pool composition as well as the overall biomass composition were taken from the C. acetobutylicum network  due to a lack of literature specific to C. difficile. A detailed composition of the biomass is available in supplementary Additional file 1: Table S14.
Simulation of growth and gene essentiality
Flux Balance Analysis (FBA)
Flux balance analysis  is a constraint-based modeling method commonly used in the study of genome-scale metabolic networks. FBA firsts creates a stoichiometry matrix (S) from the network where each row represents a metabolite and each column a reaction. The values in this matrix correspond to the stoichiometry of the metabolite in the reaction with a negative number representing consumption and a positive number representing production of the metabolite. A system of linear equations is produced by multiplying S with a column vector v representing the fluxes through each reaction. FBA creates a steady-state distribution of fluxes where the product of the previous multiplication must equal zero S???v?=?0. Since the resulting system of linear equations is undetermined, FBA uses linear programming to maximize a particular objective function Z, in our case biomass as the representation of growth, by maximizing the multiplication of a row vector c containing the weight of each reaction on Z with the column vector v used previously (maximize Z?=?c???v). Values in v are constrained by lower and upper bounds representing various factors like enzyme directionality of the reaction, capacity, uptake, secretion rates, etc. FBA finds a distribution of fluxes in the network respecting the constraints on v and maximizing Z at the same time. In our studies, the Sybil package version 1.1.11  available for the free R environment for statistical computing (version 2.15.2) was used in order to run FBA simulations. Other tools also exist that can use FBA with different interfaces like the COBRA package  that runs on the proprietary Matlab computing environment.
Synthetic Accessibility (SA)
Synthetic accessibility  is a parameter-free method to predict the essentiality of genes through their deletions in metabolic networks. SA uses network topology to calculate the number of reaction steps needed to produce the outputs (biomass) of the network from the inputs metabolites available in the growth medium. SA works by examining all reactions that use only input metabolites and marks those reactions and their products as 'accessible'. In an iterative manner, successive iterations search for new reactions that have all required substrates marked as accessible until no new reaction can be added. Each metabolite j have a synthetic accessibility value S j representing the number of iterations before this metabolite became accessible and the Synthetic Accessibility of the network as a whole, S net , is the sum of S j of each of the output metabolites. Increases in S net resulting from gene deletions are predicted as being deleterious. Synthetic accessibility is a simpler method than FBA and gives comparable results on the prediction of essential genes demonstrating that the topology of the network is the principal factor influencing essentiality. We use our own implementation of the algorithm.
Local structure similarity
The identification of local structure similarities is separated into three steps: the creation of a three dimensional model of the protein, the identification of the probable binding site, the comparison of the binding site to a dataset of known binding sites. The models used where created using I-Tasser , a tool which builds 3D models based on multiple-threading alignment and iterative fragment based simulations. Detailed methodology for I-Tasser can be found elsewhere . We used the Isocleft Finder (Kurbatova et al., ) web-interface to compare the largest cavity of each of the models (representing the binding site in 83% of cases ), identified using their own implementation of the SURFNET algorithm , to a non-redundant dataset of 7339 binding-sites of unique combinations of protein families bound to distinct ligands  using Isocleft ,. IsoCleft is a graph-matching based method for the detection of structural and chemical similarities between pairs of protein cavities. In each case, we selected the most similar match found to a protein in the IsoCleft Finder non-redundant dataset that contains human homologs. It is important to note however that the representative of such family in the non-redundant dataset may itself not be necessarily a human protein.
ML was the recipient of two undergraduate research fellowships from the Faculty of Medicine, Université de Sherbrooke. TC was partially funded by PROTEO (the Québec network for research on protein function, structure and engineering), the Fonds de Recherche du Québec en Santé (FRQ-S) and currently holds a CREMUS graduate fellowship from the Faculty of Medicine, Université de Sherbrooke. R.J.N. is a member of the Centre de Recherche Clinique étienne-Le Bel, Institute of Pharmacology of Sherbrooke, GRASP (Groupe de Recherche Axé sur la Structure des Protéines) and PROTEO.
- Voth DE, Ballard JD:Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005, 18: 247-263. 10.1128/CMR.18.2.247-263.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Rupnik M, Wilcox MH, Gerding DN:Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009, 7: 526-536. 10.1038/nrmicro2164.View ArticlePubMedGoogle Scholar
- Louie T, Miller M, Mullane K, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue Y-K: Fidaxomicin versus vancomycin for Clostridium difficile Infection. N Engl J Med. 2011, 364: 422-431. 10.1056/NEJMoa0910812.View ArticlePubMedGoogle Scholar
- Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M: Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in canada: a canadian nosocomial infection surveillance program study. Clin Infect Dis. 2009, 48: 568-576. 10.1086/596703.View ArticlePubMedGoogle Scholar
- DuPont HL: Clinical practice. Bacterial diarrhea. N Engl J Med. 2009, 361: 1560-1569. 10.1056/NEJMcp0904162.View ArticlePubMedGoogle Scholar
- Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW: Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010, 74: 309-318. 10.1016/j.jhin.2009.10.016.View ArticlePubMedGoogle Scholar
- McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR, Lee BY: The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012, 18: 282-289. 10.1111/j.1469-0691.2011.03571.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Kelly CP, LaMont JT:Clostridium difficile more difficult than ever. N Engl J Med. 2008, 359: 1932-1940. 10.1056/NEJMra0707500.View ArticlePubMedGoogle Scholar
- Shah D, Dang M-D, Hasbun R, Koo HL, Jiang Z-D, DuPont HL, Garey KW:Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010, 8: 555-564. 10.1586/eri.10.28.PubMed CentralView ArticlePubMedGoogle Scholar
- Rea MC, Alemayehu D, Ross RP, Hill C: Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection. J Med Microbiol. 2013, 62: 1369-1378. 10.1099/jmm.0.058933-0.View ArticlePubMedGoogle Scholar
- Hargreaves KR, Clokie MRJ:Clostridium difficile phages: still difficult?. Front Microbiol. 2014, 5: 184-10.3389/fmicb.2014.00184.PubMed CentralView ArticlePubMedGoogle Scholar
- Brown WR: Fecal microbiota transplantation in treatingClostridium difficileinfection.J Dig Dis 2014, epub ahead of publication (doi:10.1111-1751-2980.12160).,Google Scholar
- Humphreys DP, Wilcox MH: Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol. 2014, 21 (7): 913-923. 10.1128/CVI.00116-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Leuzzi R, Adamo R, Scarselli M: Vaccines against Clostridium difficile. Hum Vaccin Immunother. 2014, 10 (6): 1466-1477. 10.4161/hv.28428.View ArticlePubMedGoogle Scholar
- Palsson B: Systems Biology: Properties of Reconstructed Networks. 2006, Cambridge University Press, Cambridge; New YorkView ArticleGoogle Scholar
- Reed JL, Vo TD, Schilling CH, Palsson BÖ: An expanded genome-scale model of Escherichia coli K-12 (iJR904 GSM/GPR). Genome Biol. 2003, 4: R54-10.1186/gb-2003-4-9-r54.PubMed CentralView ArticlePubMedGoogle Scholar
- Thiele I, Swainston N, Fleming RMT, Hoppe A, Sahoo S, Aurich MK, Haraldsdottir H, Mo ML, Rolfsson O, Stobbe MD, Thorleifsson SG, Agren R, Bölling C, Bordel S, Chavali AK, Dobson P, Dunn WB, Endler L, Hala D, Hucka M, Hull D, Jameson D, Jamshidi N, Jonsson JJ, Juty N, Keating S, Nookaew I, Le Novnre N, Malys N, Mazein A: A community-driven global reconstruction of human metabolism. Nat Biotechnol. 2013, 31: 419-425. 10.1038/nbt.2488.View ArticlePubMedGoogle Scholar
- Ghosh S, Baloni P, Mukherjee S, Anand P, Chandra N: A multi-level multi-scale approach to study essential genes in Mycobacterium tuberculosis. BMC Syst Biol. 2013, 7: 132-10.1186/1752-0509-7-132.PubMed CentralView ArticlePubMedGoogle Scholar
- Xu P, Ge X, Chen L, Wang X, Dou Y, Xu JZ, Patel JR, Stone V, Trinh M, Evans K, Kitten T, Bonchev D, Buck GA: Genome-wide essential gene identification in Streptococcus sanguinis. Sci Rep. 2011, 1: 125-PubMed CentralPubMedGoogle Scholar
- Harrold JM, Ramanathan M, Mager DE: Network-based approaches in drug discovery and early development. Clin Pharmacol Ther. 2013, 94: 651-658. 10.1038/clpt.2013.176.PubMed CentralView ArticlePubMedGoogle Scholar
- Orth JD, Thiele I, Palsson BÖ: What is flux balance analysis?. Nat Biotechnol. 2010, 28: 245-248. 10.1038/nbt.1614.PubMed CentralView ArticlePubMedGoogle Scholar
- Wunderlich Z, Mirny LA: Using the topology of metabolic networks to predict viability of mutant strains. Biophys J. 2006, 91: 2304-2311. 10.1529/biophysj.105.080572.PubMed CentralView ArticlePubMedGoogle Scholar
- Oh Y-K, Palsson BØ, Park SM, Schilling CH, Mahadevan R: Genome-scale reconstruction of metabolic network in Bacillus subtilis based on high-throughput phenotyping and gene essentiality data. J Biol Chem. 2007, 282: 28791-28799. 10.1074/jbc.M703759200.View ArticlePubMedGoogle Scholar
- Xie L, Bourne PE: Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol. 2011, 21: 189-199. 10.1016/j.sbi.2011.01.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeno-Tarraga AM, Wang H, Holden MTG, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E: The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet. 2006, 38: 779-786. 10.1038/ng1830.View ArticlePubMedGoogle Scholar
- McAnulty MJ, Yen JY, Freedman BG, Senger RS: Genome-scale modeling using flux ratio constraints to enable metabolic engineering of clostridial metabolism in silico. BMC Syst Biol. 2012, 6: 42-10.1186/1752-0509-6-42.PubMed CentralView ArticlePubMedGoogle Scholar
- Amino acid degradation by anaerobic bacteria - annual review of biochemistry.50(1):23. ., [http://www.annualreviews.org/doi/abs/10.1146/annurev.bi.50.070181.000323]
- Jackson S, Calos M, Myers A, Self WT: Analysis of proline reduction in the nosocomial pathogen Clostridium difficile. jbasmorg. 2006, 188: 8487-8495.Google Scholar
- Nisman B: The stickland reaction. Bacteriol Rev. 1954, 18: 16-42.PubMed CentralPubMedGoogle Scholar
- Mead GC: The amino acid-fermenting clostridia. J Gen Microbiol. 1971, 67: 47-56. 10.1099/00221287-67-1-47.View ArticlePubMedGoogle Scholar
- Agren R, Liu L, Shoaie S, Vongsangnak W, Nookaew I, Nielsen J: The RAVEN toolbox and its use for generating a genome-scale metabolic model for penicillium chrysogenum. PLoS Comput Biol. 2013, 9: e1002980-10.1371/journal.pcbi.1002980.PubMed CentralView ArticlePubMedGoogle Scholar
- Gelius-Dietrich G, Desouki AA, Fritzemeier CJ, Lercher MJ: Sybil-efficient constraint-based modelling in R. BMC Syst Biol. 2013, 7: 125-10.1186/1752-0509-7-125.PubMed CentralView ArticlePubMedGoogle Scholar
- Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novnre N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED: The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 2003, 19: 524-531. 10.1093/bioinformatics/btg015.View ArticlePubMedGoogle Scholar
- Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M: Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014, 42 (Database issue): D199-D205. 10.1093/nar/gkt1076.PubMed CentralView ArticlePubMedGoogle Scholar
- Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novere N, Laibe C: BioModels database: an enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol. 2010, 4: 92-10.1186/1752-0509-4-92.PubMed CentralView ArticlePubMedGoogle Scholar
- Hafiz S, Oakley CL:Clostridium difficile: isolation and characteristics. J Med Microbiol. 1976, 9: 129-136. 10.1099/00222615-9-2-129.View ArticlePubMedGoogle Scholar
- Karasawa T, Ikoma S, Yamakawa K, Nakamura S: A defined growth medium for Clostridium difficile. Microbiology (Reading, Engl). 1995, 141 (Pt 2): 371-375. 10.1099/13500872-141-2-371.View ArticleGoogle Scholar
- Yamakawa K, Kamiya S, Meng XQ, Karasawa T, Nakamura S: Toxin production by Clostridium difficile in a defined medium with limited amino acids. J Med Microbiol. 1994, 41: 319-323. 10.1099/00222615-41-5-319.View ArticlePubMedGoogle Scholar
- Haslam SC, Ketley JM, Mitchell TJ, Stephen J, Burdon DW, Candy DC: Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol. 1986, 21: 293-297. 10.1099/00222615-21-4-293.View ArticlePubMedGoogle Scholar
- Miller CN, LoVullo ED, Kijek TM, Fuller JR, Brunton JC, Steele SP, Taft-Benz SA, Richardson AR, Kawula TH: PanG, a new ketopantoate reductase involved in pantothenate synthesis. J Bacteriol. 2013, 195: 965-976. 10.1128/JB.01740-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Böchel F, Rodriguez N, Swainston N, Wrzodek C, Czauderna T, Keller R, Mittag F, Schubert M, Glont M, Golebiewski M, van Iersel M, Keating S, Rall M, Wybrow M, Hermjakob H, Hucka M, Kell DB, Möller W, Mendes P, Zell A, Chaouiya C, Saez-Rodriguez J, Schreiber F, Laibe C, Dräger A, Le Novnre N: Path2Models: large-scale generation of computational models from biochemical pathway maps. BMC Syst Biol. 2013, 7: 116-10.1186/1752-0509-7-116.View ArticleGoogle Scholar
- Senger RS, Papoutsakis ET: Genome-scale model for clostridium acetobutylicum: part I. Metabolic network resolution and analysis. Biotechnol Bioeng. 2008, 101: 1036-1052. 10.1002/bit.22010.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee J, Yun H, Feist AM, Palsson BÖ, Lee SY: Genome-scale reconstruction and in silico analysis of the Clostridium acetobutylicum ATCC 824 metabolic network. Appl Microbiol Biotechnol. 2008, 80: 849-862. 10.1007/s00253-008-1654-4.View ArticlePubMedGoogle Scholar
- Postma PW, Lengeler JW, Jacobson GR: Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria. Microbiol Rev. 1993, 57: 543-594.PubMed CentralPubMedGoogle Scholar
- Delcour AH: Electrophysiology of bacteria. Annu Rev Microbiol. 2013, 67: 179-197. 10.1146/annurev-micro-092412-155637.View ArticlePubMedGoogle Scholar
- Hollenstein K, Dawson RJP, Locher KP: Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol. 2007, 17: 412-418. 10.1016/j.sbi.2007.07.003.View ArticlePubMedGoogle Scholar
- Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, Arnaud M, Asai K, Ashikaga S, Aymerich S, Bessieres P, Boland F, Brignell SC, Bron S, Bunai K, Chapuis J, Christiansen LC, Danchin A, Débarbouille M, Dervyn E, Deuerling E, Devine K, Devine SK, Dreesen O, Errington J, Fillinger S, Foster SJ, Fujita Y, Galizzi A, Gardan R, Eschevins C: Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A. 2003, 100: 4678-4683. 10.1073/pnas.0730515100.PubMed CentralView ArticlePubMedGoogle Scholar
- Shlomi T, Cabili MN, Herrgard MJ, Palsson BÖ, Ruppin E: Network-based prediction of human tissue-specific metabolism. Nat Biotechnol. 2008, 26: 1003-1010. 10.1038/nbt.1487.View ArticlePubMedGoogle Scholar
- Walker DJF: Development of Novel Molecular Tools for the Identification of Essential Genes of Clostridium Difficile and A Clostridium Tetracycline Inducible Promoter System. 2012Google Scholar
- Mulhbacher J, Brouillette E, Allard M, Fortier L-C, Malouin F, Lafontaine DA: Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS Pathog. 2010, 6: e1000865-10.1371/journal.ppat.1000865.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu X, Cherian PT, Lee RE, Hurdle JG: The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother. 2013, 68: 806-815. 10.1093/jac/dks493.PubMed CentralView ArticlePubMedGoogle Scholar
- Fagan RP, Fairweather NF:Clostridium difficile has two parallel and essential Sec secretion systems. J Biol Chem. 2011, 286: 27483-27493. 10.1074/jbc.M111.263889.PubMed CentralView ArticlePubMedGoogle Scholar
- Oh H, Edlund C: Mechanism of quinolone resistance in anaerobic bacteria. Clin Microbiol Infect. 2003, 9: 512-517. 10.1046/j.1469-0691.2003.00725.x.View ArticlePubMedGoogle Scholar
- Liyanage H, Young M, Kashket ER: Butanol tolerance of clostridium beijerinckii NCIMB 8052 associated with down-regulation of gldA by antisense RNA. J Mol Microbiol Biotechnol. 2000, 2: 87-93.PubMedGoogle Scholar
- Wu X, Hurdle JG: The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection. Can J Microbiol. 2014, 60: 251-254. 10.1139/cjm-2013-0903.PubMed CentralView ArticlePubMedGoogle Scholar
- Luo H, Lin Y, Gao F, Zhang C-T, Zhang R: DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res. 2014, 42 (Database issue): D574-D580. 10.1093/nar/gkt1131.PubMed CentralView ArticlePubMedGoogle Scholar
- Janoir C, Denóve C, Bouttier S, Barbut F, Hoys S, Caleechum L, Chapetn-Montes D, Pereira FC, Henriques AO, Collignon A, Monot M, Dupuy B: Adaptive strategies and pathogenesis of Clostridium difficile from in vivo transcriptomics. Infect Immun. 2013, 81: 3757-3769. 10.1128/IAI.00515-13.PubMed CentralView ArticlePubMedGoogle Scholar
- Kurbatova N, Chartier M, Zylber MI, Najmanovich R: IsoCleft Finder - a web-based tool for the detection and analysis of protein binding-site geometric and chemical similarities. F1000Res. 2013, 2: 117-PubMed CentralPubMedGoogle Scholar
- Najmanovich R, Kurbatova N, Thornton J: Detection of 3D atomic similarities and their use in the discrimination of small molecule protein-binding sites. Bioinformatics. 2008, 24: i105-i111. 10.1093/bioinformatics/btn263.View ArticlePubMedGoogle Scholar
- Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G, Clements J, Heger A, Holm L, Sonnhammer ELL, Eddy SR, Bateman A, Finn RD: The Pfam protein families database. Nucleic Acids Res. 2011, 40: D290-D301. 10.1093/nar/gkr1065.PubMed CentralView ArticlePubMedGoogle Scholar
- Göell O, Sagués F, Serrano MÁ: Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. PLoS Comput Biol. 2014, 10: e1003637-10.1371/journal.pcbi.1003637.View ArticleGoogle Scholar
- Cao J, Zhang S: A Bayesian extension of the hypergeometric test for functional enrichment analysis. Biometrics. 2014, 70: 84-94. 10.1111/biom.12122.PubMed CentralView ArticlePubMedGoogle Scholar
- Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS: DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014, 42 (Database issue): D1091-D1097. 10.1093/nar/gkt1068.PubMed CentralView ArticlePubMedGoogle Scholar
- Stobbe MD, Swertz MA, Thiele I, Rengaw T, van Kampen AH, Moerland PD: Consensus and conflict cards for metabolic pathway databases. BMC Syst Biol. 2013, 7: 50-10.1186/1752-0509-7-50.PubMed CentralView ArticlePubMedGoogle Scholar
- Latendresse M, Krummenacker M, Trupp M, Karp PD: Construction and completion of flux balance models from pathway databases. Bioinformatics. 2012, 28: 388-396. 10.1093/bioinformatics/btr681.PubMed CentralView ArticlePubMedGoogle Scholar
- Green ML, Karp PD: Genome annotation errors in pathway databases due to semantic ambiguity in partial EC numbers. Nucleic Acids Res. 2005, 33: 4035-4039. 10.1093/nar/gki711.PubMed CentralView ArticlePubMedGoogle Scholar
- Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP: The ClosTron: a universal gene knock-out system for the genus clostridium. J Microbiol Methods. 2007, 70: 452-464. 10.1016/j.mimet.2007.05.021.View ArticlePubMedGoogle Scholar
- Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP: The ClosTron: mutagenesis in clostridium refined and streamlined. J Microbiol Methods. 2010, 80: 49-55. 10.1016/j.mimet.2009.10.018.View ArticlePubMedGoogle Scholar
- De Martino D, Figliuzzi M, De Martino A, Marinari E: A scalable algorithm to explore the gibbs energy landscape of genome-scale metabolic networks. PLoS Comput Biol. 2012, 8: e1002562-10.1371/journal.pcbi.1002562.PubMed CentralView ArticlePubMedGoogle Scholar
- Rodionov DA, Vitreschak AG, Mironov AA, Gelfand MS: Comparative genomics of the methionine metabolism in Gram-positive bacteria: a variety of regulatory systems. Nucleic Acids Res. 2004, 32: 3340-3353. 10.1093/nar/gkh659.PubMed CentralView ArticlePubMedGoogle Scholar
- Karp PD, Ouzounis CA, Moore-Kochlacs C, Goldovsky L, Kaipa P, Ahrén D, Tsoka S, Darzentas N, Kunin V, Lopez-Bigas N: Expansion of the BioCyc collection of pathway/genome databases to 160 genomes. Nucleic Acids Res. 2005, 33: 6083-6089. 10.1093/nar/gki892.PubMed CentralView ArticlePubMedGoogle Scholar
- Najmanovich RJ, Torrance JW, Thornton JM: Prediction of protein function from structure: insights from methods for the detection of local structural similarities. Biotechniques. 2005, 38: 847, 849, 851-10.2144/05386TE01.View ArticlePubMedGoogle Scholar
- Jadhav A, Ezhilarasan V, Prakash Sharma O, Pan A: Clostridium-DTDB: a comprehensive database for potential drug targets of Clostridium difficile. Comput Biol Med. 2013, 43: 362-367. 10.1016/j.compbiomed.2013.01.009.View ArticlePubMedGoogle Scholar
- Shen Y, Liu J, Estiu G, Isin B, Ahn Y-Y, Lee D-S, Barabási A-L, Kapatral V, Wiest O, Oltvai ZN: Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci U S A. 2010, 107: 1082-1087. 10.1073/pnas.0909181107.PubMed CentralView ArticlePubMedGoogle Scholar
- Sidwell RW, Bailey KW, Wong M-H, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005, 68: 10-17. 10.1016/j.antiviral.2005.06.003.View ArticlePubMedGoogle Scholar
- El-Shamy A, Hotta H: Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol. 2014, 20: 7555-7569. 10.3748/wjg.v20.i24.7555.PubMed CentralView ArticlePubMedGoogle Scholar
- Trajtenberg F, Altabe S, Larrieux N, Ficarra F, de Mendoza D, Buschiazzo A, Schujman GE: Structural insights into bacterial resistance to cerulenin. FEBS J. 2014, 281: 2324-2338. 10.1111/febs.12785.View ArticlePubMedGoogle Scholar
- Caspi R, Altman T, Billington R, Dreher K, Foerster H, Fulcher CA, Holland TA, Keseler IM, Kothari A, Kubo A, Krummenacker M, Latendresse M, Mueller LA, Ong Q, Paley S, Subhraveti P, Weaver DS, Weerasinghe D, Zhang P, Karp PD: The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2014, 42 (Database issue): D459-D471. 10.1093/nar/gkt1103.PubMed CentralView ArticlePubMedGoogle Scholar
- Ren Q, Chen K, Paulsen IT: TransportDB: a comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels. Nucleic Acids Res. 2007, 35 (Database issue): D274-D279. 10.1093/nar/gkl925.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson WA, Roach PJ, Montero M, Baroja-Fernández E, Muňoz FJ, Eydallin G, Viale AM, Pozueta-Romero J: Regulation of glycogen metabolism in yeast and bacteria. FEMS Microbiol Rev. 2010, 34: 952-985.PubMed CentralView ArticlePubMedGoogle Scholar
- Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, Mering Von C, Jensen LJ: STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41 (Database issue): D808-D815. 10.1093/nar/gks1094.PubMed CentralView ArticlePubMedGoogle Scholar
- Evans RI, McClure PJ, Gould GW, Russell NJ: The effect of growth temperature on the phospholipid and fatty acyl compositions of non-proteolytic clostridium botulinum. Int J Food Microbiol. 1998, 40: 159-167. 10.1016/S0168-1605(98)00029-4.View ArticlePubMedGoogle Scholar
- Johnston NC, Goldfine H: Replacement of the aliphatic chains of Clostridium acetobutylicum by exogenous fatty acids: regulation of phospholipid and glycolipid composition. J Bacteriol. 1992, 174: 1848-1853.PubMed CentralPubMedGoogle Scholar
- Chan PP, Holmes AD, Smith AM, Tran D, Lowe TM: The UCSC archaeal genome browser: 2012 update. Nucleic Acids Res. 2012, 40 (Database issue): D646-D652. 10.1093/nar/gkr990.PubMed CentralView ArticlePubMedGoogle Scholar
- Schellenberger J, Que R, Fleming RMT, Thiele I, Orth JD, Feist AM, Zielinski DC, Bordbar A, Lewis NE, Rahmanian S, Kang J, Hyduke DR, Palsson BÖ: Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nat Protoc. 2011, 6: 1290-1307. 10.1038/nprot.2011.308.PubMed CentralView ArticlePubMedGoogle Scholar
- Roy A, Kucukural A, Zhang Y: I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010, 5: 725-738. 10.1038/nprot.2010.5.PubMed CentralView ArticlePubMedGoogle Scholar
- Laskowski RA, Luscombe NM, Swindells MB, Thornton JM: Protein clefts in molecular recognition and function. Protein Sci. 1996, 5: 2438-2452.PubMed CentralPubMedGoogle Scholar
- Laskowski R: Surfnet - a program for visualizing molecular-surfaces, cavities, and intermolecular interactions. J Mol Graph. 1995, 13: 323-330. 10.1016/0263-7855(95)00073-9.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.